INVARIANT LLC

Lobbying for KERECIS · Biotechnology company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Virginia · House · Senate · $60,000.00 income · posted Jan 20, 2026

Lobbying activity 1

Health Issues

Educate policymakers about advanced wound care technologies and patient access to skin substitutes for wound care.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.